Business Context and Reporting Period
Company: Garden Stage Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Date: September 17, 2025
Principal Executive Offices: 30th Floor, China Insurance Group Building, 141 Des Voeux Road Central, Central, Hong Kong
This filing reports on a registered direct offering completed in September 2025. The company files annual reports on Form 20-F.
Key Financial Metrics
Capital Raised: Approximately $4,900,000 in net proceeds.
Shares Issued: 144,117,647 ordinary shares.
Offering Price: $0.034 per share.
Par Value: $0.0001 per share.
Use of Proceeds: Working capital and general corporate purposes.
The filing does not provide specific values for revenue, profit, cash flow, operating margins, total debt, or liquidity ratios. The document focuses exclusively on the capital raise transaction.
Material Changes
The primary material change reported is the increase in share count and equity capital resulting from the September 2025 Registered Direct Offering. The offering closed on September 15, 2025, following the execution of securities purchase agreements on September 12, 2025.
Guidance, Outlook, and Risks
Management Commentary: The company intends to utilize the net proceeds for working capital and general corporate purposes. No specific operational guidance or financial projections were provided in this filing.
Risks and Contingencies: The filing includes a standard forward-looking statements disclaimer. It notes that actual results may differ materially from expectations due to inherent uncertainties, risks, and changes in circumstances. Investors are directed to the risks described in the Company's annual report on Form 20-F for the year ended December 31, 2024, for a comprehensive list of risk factors.
Investor Verification Checklist
- Verify the dilution impact of the issuance of 144,117,647 new shares on existing shareholders.
- Confirm the identity of the "Purchasers" involved in the registered direct offering via the attached Securities Purchase Agreement (Exhibit 10.1).
- Review the Form 20-F for the year ended December 31, 2024, to assess the company's historical financial health and risk profile.
- Monitor future filings to track the actual deployment of the $4.9 million in net proceeds.